Sun Pharma has been granted exclusive rights to market Winlevi acne cream in the United States and Canada

Sun Pharma and Cassiopea SpA, a speciality pharma company, announced the completion of their exclusive licence and supply agreements for Winlevi cream, which is used to treat acne vulgaris in patients aged 12 and up.

According to a joint statement, the agreements will take effect on August 31, 2021.

Sun Pharma now has the exclusive right to commercialise Winlevi in the US and Canada. Cassiopea will be the exclusive supplier of the product, which is expected to be available in the US in the fourth quarter of 2021, it added.

Sun Pharma, North America CEO Abhay Gandhi said the expiration of the applicable waiting period under the US Hart-Scott-Rodino Antitrust Improvements Act of 1976 (HSR Act) clears the path for making Winlevi available to patients and healthcare providers in the US and Canada.

“With Winlevi, a unique product with a new mechanism of action for the topical treatment of acne vulgaris, we have further expanded our basket of innovative products to serve patients better,” he added.

The US Food and Drug Administration (USFDA) approved Winlevi (clascoterone cream 1 percent) in August 2020 for the topical treatment of acne vulgaris in patients 12 years and older, the statement said.

“We are very pleased that Winlevi will soon be widely available to dermatology healthcare providers and their patients in the US and Canada, benefiting from Sun Pharma’s strong established dermatology presence,” Cassiopea SpA CEO Diana Harbort said.

This transaction now allows Cassiopea to focus on its innovative dermatology pipeline, she added.

“We are very pleased that Winlevi will soon be widely available to dermatology healthcare providers and their patients in the US and Canada, benefiting from Sun Pharma’s strong established dermatology presence,” Cassiopea SpA CEO Diana Harbort said.

This transaction now allows Cassiopea to focus on its innovative dermatology pipeline, she added.

Shares of Sun Pharmaceutical Industries were trading at Rs 793.50 per scrip on BSE, up 0.88 percent from its previous close.

Medically Speaking

Recent Posts

New Research Aims to Uncover Molecular Factors Behind Malaria’s Deadliest Strain

Uncovering the Molecular Secrets of Malaria’s Deadliest Strain: A New Research Project Malaria remains one…

3 hours ago

Sunlight and Skin Cancer: The Hidden Dangers of UV Exposure

Sunlight Can Cause Cancer: Prolonged exposure to sunlight and exposure to UV (ultraviolet) rays can…

3 hours ago

Microplastics in Humans: A Hidden Health and Environmental Crisis

https://youtu.be/mlBSCMO2NQg?si=UfC4C3WgtMZ9DhB4 Humans Are Swallowing Microplastics: A Hidden Environmental and Health Crisis In recent years, microplastics…

3 hours ago

Obesity Drugs: Weight Loss Solutions, Benefits, and Risks

https://youtu.be/H_aiXVvX8Eg?si=vH4Arvq7pbpXERMF Obesity Drugs: A Comprehensive Guide to Weight Loss Solutions Obesity is one of the…

3 hours ago

Cold Hands & Feet in Winter: Causes, Remedies, and Prevention Tips

https://youtu.be/LZi8Jn0tAA8?si=bpMPudQxl1LUdgXN Cold Hands & Feet in Winter: Causes, Remedies, and Prevention Tips Winter can be…

4 hours ago

Dysautonomia: The Silent Illness Affecting Millions Globally

Dysautonomia: The Silent Illness Impacting Millions of People Worldwide Dysautonomia is an umbrella term used…

2 days ago